Back to top

Image: Bigstock

Aerie Pharmaceuticals, Inc.

Read MoreHide Full Article

Aerie received a significant boost with the recent approval of lead drug Rhopressa.The approval came ahead of the PDUFA date in Feb. The approval will significantly boost Aerie's prospects as glaucoma is one of the largest segments in the global ophthalmic market. Aerie is also evaluating Roclatan, a once-daily, quadrupleaction fixed-dose combination of Rhopressa and Xalatan. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta was recently approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Aerie’s shares have outperformed the industry in the last one year.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aerie Pharmaceuticals, Inc. (AERI) - free report >>

Published in